
|Articles|February 9, 2022
Daily OTC Pearl: Vazalore
Author(s)Saro Arakelians, PharmD
Vazalore has been shown to cause fewer stomach-related adverse effects than traditional aspirin.
Advertisement
OTC/Lifestyle Pearl of the Day: Vazalore
Indication: Valazore, a new type of aspirin, is a non-steroidal anti-inflammatory drug approved by the FDA in March 2021 as an OTC product that helps prevent blood clots.
Insight:
- Classified as a salicylate.
- Compared to traditional aspirin, Vazalore has been shown to cause fewer stomach-related adverse effects, such as ulcers and damage to the stomach.
- Dosing: Coronary artery bypass graft 325 mg once daily (start 6 hours after procedure) for 1 year. Percutaneous transluminal coronary angioplasty 325 mg 2 hours before surgery, then 160 mg–325 mg once daily. Carotid endarterectomy 80 mg once daily to 650 mg twice daily (start before surgery).
- The higher dose of Vazalore (325 mg) works by blocking certain chemicals in the body that cause pain, fever, and swelling.
- Caution: Do not take if history of bleeding and speak to the provider before starting the medication.
- If pregnant, discuss the use of Vazalore with a health care provider first.
- Available dosage: Caps 81 mg—12, 30; 325 mg—30.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Enfortumab Vedotin Plus Pembrolizumab Shows Promise as a Platinum-Free Option in Earlier Bladder Cancer
2
FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery
3
Advancing the Role of Pharmacy Technicians in Hazardous Drug Compounding
4
Potential Benefits of GLP-1 Agonists in Reducing Chemotherapy-Related Toxicities in Breast Cancer
5









































































































































































































